Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Open access
Mlcochova, Petra, Kemp, Steven A., Dhar, Mahesh Shanker, Papa, Guido, Meng, Bo, Ferreira, Isabella A. T. M., Datir, Rawlings, Collier, Dami A., Albecka, Anna, Singh, Sujeet, Pandey, Rajesh, Brown, Jonathan, Zhou, Jie, Goonawardane, Niluka, Mishra, Swapnil, Whittaker, Charles, Mellan, Thomas, Marwal, Robin, Datta, Meena, Sengupta, Shantanu, Ponnusamy, Kalaiarasan, Radhakrishnan, Venkatraman Srinivasan, Abdullahi, Adam, Charles, Oscar, Chattopadhyay, Partha, Devi, Priti, Caputo, Daniela, Peacock, Tom, Wattal, Chand, Goel, Neeraj, Satwik, Ambrish, Vaishya, Raju, Agarwal, Meenakshi, The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Chauhan, Himanshu, Dikid, Tanzin, Gogia, Hema, Lall, Hemlata, Verma, Kaptan, Dhar, Mahesh Shanker, Singh, Manoj K., Soni, Namita, Meena, Namonarayan, Madan, Preeti, Singh, Priyanka, Sharma, Ramesh, Sharma, Rajeev, Kabra, Sandhya, Kumar, Sattender, Kumari, Swati, Sharma, Uma, Chaudhary, Urmila, Sivasubbu, Sridhar, Scaria, Vinod, Oberoi, J. K., Raveendran, Reena, Datta, S., Das, Saumitra, Maitra, Arindam, Chinnaswamy, Sreedhar, Biswas, Nidhan Kumar, Parida, Ajay, Raghav, Sunil K., Prasad, Punit, Sarin, Apurva, Mayor, Satyajit, Ramakrishnan, Uma, Palakodeti, Dasaradhi, Seshasayee, Aswin Sai Narain, Thangaraj, K., Bashyam, Murali Dharan, Dalal, Ashwin, Bhat, Manoj, Shouche, Yogesh, Pillai, Ajay, Abraham, Priya, Potdar, Varsha Atul, Cherian, Sarah S., Desai, Anita Sudhir, Pattabiraman, Chitra, Manjunatha, M. V., Mani, Reeta S., Udupi, Gautam Arunachal, Nandicoori, Vinay, Tallapaka, Karthik Bharadwaj, Sowpati, Divya Tej, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kawabata, Ryoko, Morizako, Nanami, Sadamasu, Kenji, Asakura, Hiroyuki, Nagashima, Mami, Yoshimura, Kazuhisa, Ito, Jumpei, Kimura, Izumi, Uriu, Keiya, Kosugi, Yusuke, Suganami, Mai, Oide, Akiko, Yokoyama, Miyabishara, Chiba, Mika, Saito, Akatsuki, Butlertanaka, Erika P., Tanaka, Yuri L., Ikeda, Terumasa, Motozono, Chihiro, Nasser, Hesham, Shimizu, Ryo, Yuan, Yue, Kitazato, Kazuko, Hasebe, Haruyo, Nakagawa, So, Wu, Jiaqi, Takahashi, Miyoko, Fukuhara, Takasuke, Shimizu, Kenta, Tsushima, Kana, Kubo, Haruko, Shirakawa, Kotaro, Kazuma, Yasuhiro, Nomura, Ryosuke, Horisawa, Yoshihito, Takaori-Kondo, Akifumi, Tokunaga, Kenzo, Ozono, Seiya, The CITIID-NIHR BioResource COVID-19 Collaboration, Baker, Stephen, Dougan, Gordon, Hess, Christoph, Kingston, Nathalie, Lehner, Paul J., Lyons, Paul A., Matheson, Nicholas J., Owehand, Willem H., Saunders, Caroline, Summers, Charlotte, Thaventhiran, James E. D., Toshner, Mark, Weekes, Michael P., Maxwell, Patrick, Shaw, Ashley, Bucke, Ashlea, Calder, Jo, Canna, Laura, Domingo, Jason, Elmer, Anne, Fuller, Stewart, Harris, Julie, Hewitt, Sarah, Kennet, Jane, Jose, Sherly, Kourampa, Jenny, Meadows, Anne, O’Brien, Criona, Price, Jane, Publico, Cherry, Rastall, Rebecca, Ribeiro, Carla, Rowlands, Jane, Ruffolo, Valentina, Tordesillas, Hugo, Bullman, Ben, Dunmore, Benjamin J., Fawke, Stuart, Gräf, Stefan, Hodgson, Josh, Huang, Christopher, Hunter, Kelvin, Jones, Emma, Legchenko, Ekaterina, Matara, Cecilia, Martin, Jennifer, Mescia, Federica, O’Donnell, Ciara, Pointon, Linda, Pond, Nicole, Shih, Joy, Sutcliffe, Rachel, Tilly, Tobias, Treacy, Carmen, Tong, Zhen, Wood, Jennifer, Wylot, Marta, Bergamaschi, Laura, Betancourt, Ariana, Bower, Georgie, Cossetti, Chiara, De Sa, Aloka, Epping, Madeline, Fawke, Stuart, Gleadall, Nick, Grenfell, Richard, Hinch, Andrew, Huhn, Oisin, Jackson, Sarah, Jarvis, Isobel, Krishna, Ben, Lewis, Daniel, Marsden, Joe, Nice, Francesca, Okecha, Georgina, Omarjee, Ommar, Perera, Marianne, Potts, Martin, Richoz, Nathan, Romashova, Veronika, Yarkoni, Natalia Savinykh, Sharma, Rahul, Stefanucci, Luca, Stephens, Jonathan, Strezlecki, Mateusz, Turner, Lori, De Bie, Eckart M. D. D., Bunclark, Katherine, Josipovic, Masa, Mackay, Michael, Rossi, Sabrina, Selvan, Mayurun, Spencer, Sarah, Yong, Cissy, Allison, John, Butcher, Helen, Caputo, Daniela, Clapham-Riley, Debbie, Dewhurst, Eleanor, Furlong, Anita, Graves, Barbara, Gray, Jennifer, Ivers, Tasmin, Kasanicki, Mary, Le Gresley, Emma, Linger, Rachel, Meloy, Sarah, Muldoon, Francesca, Ovington, Nigel, Papadia, Sofia, Phelan, Isabel, Stark, Hannah, Stirrups, Kathleen E., Townsend, Paul, Walker, Neil, Webster, Jennifer, Scholtes, Ingrid, Hein, Sabine, King, Rebecca, Mavousian, Antranik, Lee, Joo Hyeon, Bassi, Jessica, Silacci-Fegni, Chiara, Saliba, Christian, Pinto, Dora, Irie, Takashi, Yoshida, Isao, Hamilton, William L., Sato, Kei, Bhatt, Samir, Flaxman, Seth, James, Leo C., Corti, Davide, Piccoli, Luca, Barclay, Wendy S., Rakshit, Partha, Agrawal, Anurag, Gupta, Ravindra K.·2021·Nature

Published version of a preprint

Abstract

The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha) 1 . In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03944-y

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Extended Data Fig. 1 Delta variant B.1.617.2 shows reduced sensitivity to monoclonal antibodies. Neutralisation by a panel of NTD- and RBD-specific mAbs against WT and B.1.617.2 mutant SARS-CoV-2 pseudotyped viruses. a. Neutralisation of WT D614 (black) and B.1.617.2 mutant (blue) pseudotyped SARS-CoV-2-VSV by 6 selected mAbs from one representative experiment out of 2 independent experiments. S2X333 is an NTD-specific mAb, S2D97, S2E12 and S2X58 are RBM-specific mAbs, while S2X35 and S2X305 are non-RBM mAbs. b. Neutralisation of WT and B.1.617.2 VSV by 38 mAbs targeting NTD (n = 3), RBM (n = 26, including 5 clinical stage mAb) and non-RBM (n = 9). Shown are the mean IC50 values (ng/ml) from 2 independent experiments. Non-neutralising IC50 titers were set at 104 ng/ml. c. Neutralisation shown as mean IC50 values (upper panel) and average fold change of B.1.617.2 relative to WT (lower panel) of 38 mAbs tested in 2 independent experiments (including 5 clinical-stage mAbs), tested using Vero E6 cells expressing TMPRSS2. d-e, Neutralisation of WT D614 (black) and B.1.617.2 mutant (blue/red) pseudotyped SARS-CoV-2-VSV by 5 clinical-stage mAbs using Vero E6 cells expressing TMPRSS2 (d) or not (e). Shown is one representative experiment out of 2 independent experiments.
Extended Data Fig. 1 Delta variant B.1.617.2 shows reduced sensitivity to monoclonal antibodies. Neutralisation by a panel of NTD- and RBD-specific mAbs against WT and B.1.617.2 mutant SARS-CoV-2 pseudotyped viruses. a. Neutralisation of WT D614 (black) and B.1.617.2 mutant (blue) pseudotyped SARS-CoV-2-VSV by 6 selected mAbs from one representative experiment out of 2 independent experiments. S2X333 is an NTD-specific mAb, S2D97, S2E12 and S2X58 are RBM-specific mAbs, while S2X35 and S2X305 are non-RBM mAbs. b. Neutralisation of WT and B.1.617.2 VSV by 38 mAbs targeting NTD (n = 3), RBM (n = 26, including 5 clinical stage mAb) and non-RBM (n = 9). Shown are the mean IC50 values (ng/ml) from 2 independent experiments. Non-neutralising IC50 titers were set at 104 ng/ml. c. Neutralisation shown as mean IC50 values (upper panel) and average fold change of B.1.617.2 relative to WT (lower panel) of 38 mAbs tested in 2 independent experiments (including 5 clinical-stage mAbs), tested using Vero E6 cells expressing TMPRSS2. d-e, Neutralisation of WT D614 (black) and B.1.617.2 mutant (blue/red) pseudotyped SARS-CoV-2-VSV by 5 clinical-stage mAbs using Vero E6 cells expressing TMPRSS2 (d) or not (e). Shown is one representative experiment out of 2 independent experiments.CC BY · PubMed Central
Extended Data Fig. 2 Spike cleavage in B.1.617.2 virions compared to B.1.1.7. and spike mediated cell-cell fusion. a. Representative western blot analysis of spike and nucleoprotein present in SARS-CoV-2 particles from the indicated viruses produced in Vero E6 ACE2/TMPRSS2 cells 48 h post infection. The arrowhead identifies the S2 subunit. b. Quantification of cleaved and full-length spike of the indicated viruses. c. Schematic of cell-cell fusion assay. d. Reconstructed images at 10 h of GFP positive syncytia formation. Scale bars represent 400 mm. e. western blot of cell lysates 48 h after transfection of spike plasmids.f,g. Quantification of cell-cell fusion kinetics showing percentage of green area to total cell area over time. Mean is plotted with error bars representing SEM. h. Comparison of impact of post vaccine sera (n = 2) on PV neutralisation (top) and cell-cell fusion (bottom), comparing WT and Delta variant B.1.671.2. Data are representative of at least two independent experiments.
Extended Data Fig. 2 Spike cleavage in B.1.617.2 virions compared to B.1.1.7. and spike mediated cell-cell fusion. a. Representative western blot analysis of spike and nucleoprotein present in SARS-CoV-2 particles from the indicated viruses produced in Vero E6 ACE2/TMPRSS2 cells 48 h post infection. The arrowhead identifies the S2 subunit. b. Quantification of cleaved and full-length spike of the indicated viruses. c. Schematic of cell-cell fusion assay. d. Reconstructed images at 10 h of GFP positive syncytia formation. Scale bars represent 400 mm. e. western blot of cell lysates 48 h after transfection of spike plasmids.f,g. Quantification of cell-cell fusion kinetics showing percentage of green area to total cell area over time. Mean is plotted with error bars representing SEM. h. Comparison of impact of post vaccine sera (n = 2) on PV neutralisation (top) and cell-cell fusion (bottom), comparing WT and Delta variant B.1.671.2. Data are representative of at least two independent experiments.CC BY · PubMed Central
Extended Data Fig. 3 B.1.617.2 spike confers increased cell entry. a. diagram showing mutations present in spike plasmids used for cell entry PV experiments b. Single round infectivity on different cell targets by spike B.1.617.1 and B.1.617.1 versus WT (Wuhan-1 D614G) PV produced in 293T cells. Data are representative of three independent experiments. Statistics were performed using unpaired Student t test. c. Western blotting of supernatants from transfected 293T probing for S2 and p24 in PV and showing no spike control.
Extended Data Fig. 3 B.1.617.2 spike confers increased cell entry. a. diagram showing mutations present in spike plasmids used for cell entry PV experiments b. Single round infectivity on different cell targets by spike B.1.617.1 and B.1.617.1 versus WT (Wuhan-1 D614G) PV produced in 293T cells. Data are representative of three independent experiments. Statistics were performed using unpaired Student t test. c. Western blotting of supernatants from transfected 293T probing for S2 and p24 in PV and showing no spike control.CC BY · PubMed Central
Extended Data Fig. 4 Breakthrough SARS-CoV-2 infections amongst vaccinated health care workers (HCW). a. Case frequencies of five most commonly occurring SARS CoV-2 lineages over a six week period from March to April 2021 for Delhi b,c,d. case frequency graph for hospital 1, 2 and 3 respectively by date of testing. e. Comparison of IgG antibody titres between a control group of vaccinated individuals receiving two doses of ChadOx-1 who have not been infected with SARS-CoV-2, with vaccinated healthcare workers who had received two doses and subsequently tested positive for SARS-CoV-2. f. Ct values in nose/throat swabs from HCW testing positive by hospital. Bars represent Mean and 95% CI. Ct values were compared using the Student t test.
Extended Data Fig. 4 Breakthrough SARS-CoV-2 infections amongst vaccinated health care workers (HCW). a. Case frequencies of five most commonly occurring SARS CoV-2 lineages over a six week period from March to April 2021 for Delhi b,c,d. case frequency graph for hospital 1, 2 and 3 respectively by date of testing. e. Comparison of IgG antibody titres between a control group of vaccinated individuals receiving two doses of ChadOx-1 who have not been infected with SARS-CoV-2, with vaccinated healthcare workers who had received two doses and subsequently tested positive for SARS-CoV-2. f. Ct values in nose/throat swabs from HCW testing positive by hospital. Bars represent Mean and 95% CI. Ct values were compared using the Student t test.CC BY · PubMed Central
Fig. 1 Rapid expansion of Delta variant B.1.617.2 cases in India and reduced sensitivity to neutralizing antibodies from sera derived following infection and vaccination. a, Proportion of lineages in incident cases of SARS-CoV-2 in India 2020-2021. b, Surface representation of the SARS-CoV-2 B.1.671.2 spike trimer (PDB: 6ZGE). Red, L19R; green, del157/158; blue, L452R; yellow, T478K. The white dotted box indicates the location of the D950N substitution (orange). c, Neutralization of the Delta variant by convalescent human serum from mid-2020. Fold change in serum neutralization of 100 TCID50 of B.1.17 (Alpha), B.1.351 (Beta) and B.1617.2 (Delta) variants relative to WT (IC19); n = 12. Shown is the ID50, the serum dilution required for 50% virus inhibition, expressed as GMT (from technical replicates) with s.d. d, Neutralization of B.1617.2 live virus by sera from vaccinated individuals (n = 10 ChAdOx1 or n = 10 BNT12b2), compared with B.1.1.7 and Wuhan-1 WT. The graph presents the average of two independent experiments. e, Neutralization of B.1.617 spike PV and WT (Wuhan-1 D614G) by vaccine sera (n = 33 ChAdOx1 or n = 32 BNT162b2). The data are representative of two independent experiments each with two technical replicates. *P < 0.05, **P < 0.01, ****P < 0.0001 (Wilcoxon matched-pairs signed rank test); NS, not significant.
Fig. 1 Rapid expansion of Delta variant B.1.617.2 cases in India and reduced sensitivity to neutralizing antibodies from sera derived following infection and vaccination. a, Proportion of lineages in incident cases of SARS-CoV-2 in India 2020-2021. b, Surface representation of the SARS-CoV-2 B.1.671.2 spike trimer (PDB: 6ZGE). Red, L19R; green, del157/158; blue, L452R; yellow, T478K. The white dotted box indicates the location of the D950N substitution (orange). c, Neutralization of the Delta variant by convalescent human serum from mid-2020. Fold change in serum neutralization of 100 TCID50 of B.1.17 (Alpha), B.1.351 (Beta) and B.1617.2 (Delta) variants relative to WT (IC19); n = 12. Shown is the ID50, the serum dilution required for 50% virus inhibition, expressed as GMT (from technical replicates) with s.d. d, Neutralization of B.1617.2 live virus by sera from vaccinated individuals (n = 10 ChAdOx1 or n = 10 BNT12b2), compared with B.1.1.7 and Wuhan-1 WT. The graph presents the average of two independent experiments. e, Neutralization of B.1.617 spike PV and WT (Wuhan-1 D614G) by vaccine sera (n = 33 ChAdOx1 or n = 32 BNT162b2). The data are representative of two independent experiments each with two technical replicates. *P < 0.05, **P < 0.01, ****P < 0.0001 (Wilcoxon matched-pairs signed rank test); NS, not significant.CC BY · PubMed Central
Fig. 2 Delta variant live virus replication kinetics and spike-mediated infectivity. a-d, Live virus replication comparing B.1.1.7 with B.1.617.2. Calu-3 cells were infected with variants at an MOI of 0.1. a, Viral loads measured by qPCR in cell lysates. b, Viral protein levels in cell lysates. c, d, Live virus produced from infected Calu-3 cell supernatants was collected and used to infect permissive Vero E6 ACE2/TMPRSS2 cells to measure viral loads (c) or TCID50 ml−1 (d). e, f, Virus replication kinetics in the HAE system. g, Live virus replication in airway epithelial organoid cultures. Airway epithelial organoids were infected with the SARS-CoV-2 variants B.1.1.7 and B.1.617.2 at an MOI of 1. Cells were lysed and total RNA was isolated. qPCR was used to determine the number of copies of the nucleoprotein gene in cells and the infectivity of cell-free virus measured by infection of Vero E6 ACE2/TMPRSS2 cells. The data are representative of two independent experiments. dpi, days post-infection. h, i, Western blots of PV virions (h) and cell lysates (i) of 293T producer cells following transfection with plasmids expressing lentiviral vectors and SARS-CoV-2 S B.1.617.1 and Delta variant B.1.617.2 versus WT (Wuhan-1 with D614G), probed with antibodies to HIV-1 p24 and SARS-Cov-2 S2. j, Calu-3 cell entry by spike B.1.617.2 and B.1.617.1 versus WT D614G parental plasmid PVs. The data are representative of three independent experiments. k, Growth kinetics of B.1.617.1 and B.1.617.2 variants. Viral isolates of B.1.617.1 and B.1.617.2 were inoculated into Calu-3 cells, and viral RNA in the culture supernatant was quantified by real-time RT-PCR. The TCID50 of released virus in supernatant was measured over time. Assays were performed in quadruplicate. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The data are representative of two independent experiments. Uninfected cells are represented by a minus symbol. NP, nucleocapsid protein.
Fig. 2 Delta variant live virus replication kinetics and spike-mediated infectivity. a-d, Live virus replication comparing B.1.1.7 with B.1.617.2. Calu-3 cells were infected with variants at an MOI of 0.1. a, Viral loads measured by qPCR in cell lysates. b, Viral protein levels in cell lysates. c, d, Live virus produced from infected Calu-3 cell supernatants was collected and used to infect permissive Vero E6 ACE2/TMPRSS2 cells to measure viral loads (c) or TCID50 ml−1 (d). e, f, Virus replication kinetics in the HAE system. g, Live virus replication in airway epithelial organoid cultures. Airway epithelial organoids were infected with the SARS-CoV-2 variants B.1.1.7 and B.1.617.2 at an MOI of 1. Cells were lysed and total RNA was isolated. qPCR was used to determine the number of copies of the nucleoprotein gene in cells and the infectivity of cell-free virus measured by infection of Vero E6 ACE2/TMPRSS2 cells. The data are representative of two independent experiments. dpi, days post-infection. h, i, Western blots of PV virions (h) and cell lysates (i) of 293T producer cells following transfection with plasmids expressing lentiviral vectors and SARS-CoV-2 S B.1.617.1 and Delta variant B.1.617.2 versus WT (Wuhan-1 with D614G), probed with antibodies to HIV-1 p24 and SARS-Cov-2 S2. j, Calu-3 cell entry by spike B.1.617.2 and B.1.617.1 versus WT D614G parental plasmid PVs. The data are representative of three independent experiments. k, Growth kinetics of B.1.617.1 and B.1.617.2 variants. Viral isolates of B.1.617.1 and B.1.617.2 were inoculated into Calu-3 cells, and viral RNA in the culture supernatant was quantified by real-time RT-PCR. The TCID50 of released virus in supernatant was measured over time. Assays were performed in quadruplicate. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The data are representative of two independent experiments. Uninfected cells are represented by a minus symbol. NP, nucleocapsid protein.CC BY · PubMed Central
Fig. 3 SARS-CoV-2 B.1.617.2 infection in vaccinated HCWs. a-c, Maximum-likelihood phylogenies of vaccine breakthrough SARS-CoV-2 sequences among vaccinated HCWs at three centres. Phylogenies were inferred with IQTREE2 with 1,000 bootstrap replicates. SNPs, single nucleotide polymorphisms.
Fig. 3 SARS-CoV-2 B.1.617.2 infection in vaccinated HCWs. a-c, Maximum-likelihood phylogenies of vaccine breakthrough SARS-CoV-2 sequences among vaccinated HCWs at three centres. Phylogenies were inferred with IQTREE2 with 1,000 bootstrap replicates. SNPs, single nucleotide polymorphisms.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Research works printed but not linked: 2

  1. Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493–497 (1938).
  2. Papa, G. et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog. 17, e1009246 (2021). · DOI · Paper page

Cited by

See all 1,337

Metadata

Authors
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., Sengupta, S., Ponnusamy, K., Radhakrishnan, V. S., Abdullahi, A., Charles, O., Chattopadhyay, P., Devi, P., Caputo, D., Peacock, T., Wattal, C., Goel, N., Satwik, A., Vaishya, R., Agarwal, M., The Indian SARS-CoV-2 Genomics Consortium (INSACOG), Chauhan, H., Dikid, T., Gogia, H., Lall, H., Verma, K., Dhar, M. S., Singh, M. K., Soni, N., Meena, N., Madan, P., Singh, P., Sharma, R., Sharma, R., Kabra, S., Kumar, S., Kumari, S., Sharma, U., Chaudhary, U., Sivasubbu, S., Scaria, V., Oberoi, J. K., Raveendran, R., Datta, S., Das, S., Maitra, A., Chinnaswamy, S., Biswas, N. K., Parida, A., Raghav, S. K., Prasad, P., Sarin, A., Mayor, S., Ramakrishnan, U., Palakodeti, D., Seshasayee, A. S. N., Thangaraj, K., Bashyam, M. D., Dalal, A., Bhat, M., Shouche, Y., Pillai, A., Abraham, P., Potdar, V. A., Cherian, S. S., Desai, A. S., Pattabiraman, C., Manjunatha, M. V., Mani, R. S., Udupi, G. A., Nandicoori, V., Tallapaka, K. B., Sowpati, D. T., The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kawabata, R., Morizako, N., Sadamasu, K., Asakura, H., Nagashima, M., Yoshimura, K., Ito, J., Kimura, I., Uriu, K., Kosugi, Y., Suganami, M., Oide, A., Yokoyama, M., Chiba, M., Saito, A., Butlertanaka, E. P., Tanaka, Y. L., Ikeda, T., Motozono, C., Nasser, H., Shimizu, R., Yuan, Y., Kitazato, K., Hasebe, H., Nakagawa, S., Wu, J., Takahashi, M., Fukuhara, T., Shimizu, K., Tsushima, K., Kubo, H., Shirakawa, K., Kazuma, Y., Nomura, R., Horisawa, Y., Takaori-Kondo, A., Tokunaga, K., Ozono, S., The CITIID-NIHR BioResource COVID-19 Collaboration, Baker, S., Dougan, G., Hess, C., Kingston, N., Lehner, P. J., Lyons, P. A., Matheson, N. J., Owehand, W. H., Saunders, C., Summers, C., Thaventhiran, J. E. D., Toshner, M., Weekes, M. P., Maxwell, P., Shaw, A., Bucke, A., Calder, J., Canna, L., Domingo, J., Elmer, A., Fuller, S., Harris, J., Hewitt, S., Kennet, J., Jose, S., Kourampa, J., Meadows, A., O’Brien, C., Price, J., Publico, C., Rastall, R., Ribeiro, C., Rowlands, J., Ruffolo, V., Tordesillas, H., Bullman, B., Dunmore, B. J., Fawke, S., Gräf, S., Hodgson, J., Huang, C., Hunter, K., Jones, E., Legchenko, E., Matara, C., Martin, J., Mescia, F., O’Donnell, C., Pointon, L., Pond, N., Shih, J., Sutcliffe, R., Tilly, T., Treacy, C., Tong, Z., Wood, J., Wylot, M., Bergamaschi, L., Betancourt, A., Bower, G., Cossetti, C., De Sa, A., Epping, M., Fawke, S., Gleadall, N., Grenfell, R., Hinch, A., Huhn, O., Jackson, S., Jarvis, I., Krishna, B., Lewis, D., Marsden, J., Nice, F., Okecha, G., Omarjee, O., Perera, M., Potts, M., Richoz, N., Romashova, V., Yarkoni, N. S., Sharma, R., Stefanucci, L., Stephens, J., Strezlecki, M., Turner, L., De Bie, E. M. D. D., Bunclark, K., Josipovic, M., Mackay, M., Rossi, S., Selvan, M., Spencer, S., Yong, C., Allison, J., Butcher, H., Caputo, D., Clapham-Riley, D., Dewhurst, E., Furlong, A., Graves, B., Gray, J., Ivers, T., Kasanicki, M., Le Gresley, E., Linger, R., Meloy, S., Muldoon, F., Ovington, N., Papadia, S., Phelan, I., Stark, H., Stirrups, K. E., Townsend, P., Walker, N., Webster, J., Scholtes, I., Hein, S., King, R., Mavousian, A., Lee, J. H., Bassi, J., Silacci-Fegni, C., Saliba, C., Pinto, D., Irie, T., Yoshida, I., Hamilton, W. L., Sato, K., Bhatt, S., Flaxman, S., James, L. C., Corti, D., Piccoli, L., Barclay, W. S., Rakshit, P., Agrawal, A., & Gupta, R. K.
Affiliations
  • University of Cambridge (GB)
  • MRC Laboratory of Molecular Biology (GB)
  • National Center for Disease Control (IN)
  • Institute of Genomics and Integrative Biology (IN)
  • Imperial College London (GB)
  • University College London (GB)
  • Sir Ganga Ram Hospital (IN)
  • Indraprastha Apollo Hospitals (IN)
  • National Institute of Biomedical Genomics (IN)
  • Institute of Life Sciences (IN)
  • National Centre for Biological Sciences (IN)
  • Centre for DNA Fingerprinting and Diagnostics (IN)
  • National Centre for Cell Science (IN)
  • ICMR-National Institute of Virology (IN)
  • National Institute of Mental Health and Neurosciences (IN)
  • Centre for Cellular and Molecular Biology (IN)
  • Hiroshima University (JP)
  • Tokyo Metropolitan Institute of Public Health (JP)
  • Institute of Medical Science, The University of Tokyo (JP)
  • University of Miyazaki (JP)
  • Kumamoto University (JP)
  • Tokai University (JP)
  • Hokkaido University (JP)
  • Kyoto University (JP)
  • National Institute of Infectious Diseases (JP)
  • NIHR BioResource (GB)
  • Africa Health Research Institute (ZA)
  • University of Oxford (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Vir Biotechnology (Switzerland) (CH)
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
  • Japan Science and Technology Agency (JP)
Corresponding author
  • Rakshit, Partha
  • Agrawal, Anurag
  • Gupta, Ravindra K.
ORCID
Venue
Nature
Published
2021-09-06
Volume
599
Issue
7883
Pages
114-119
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3198233589
Cited by
1,337
References
67
Citations by year
2026: 46 · 2025: 92 · 2024: 147 · 2023: 281 · 2022: 614 · 2021: 155
FWCI
95.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo
  • Greater South Information System
Funders
  • Bill and Melinda Gates Foundation (OPP 1175094)
  • Japan Agency for Medical Research and Development (CREST, 20fk0108413h0001)
  • Wellcome Trust (108070/Z/15/Z, 108082/A/15/Z, 108082, WT108082AIA, MR/W005611/1, DEL-15-006, 200594/Z/16/Z, 081772)
  • UK Research and Innovation (MR/W005611/1/)
  • Cancer Research UK (22310)
  • National Institute for Health and Care Research (OPP1175094, DEL-15-006)
  • Academy of Medical Sciences (SBF004\1080)
  • Rosetrees Trust
  • Evelyn Trust (20/75)
  • NIHR BioResource
  • Medical Research Council (MC_PC_17230, MR/R015600/1, MR/W005611/1, MC_PC_19012, COVID-19)
  • Engineering and Physical Sciences Research Council (EP/V002910/1, EP/V002910/2, MR/W005611/1)
  • Japan Society for the Promotion of Science (18H02662, 19K22968, 18KK0447, 21K07060)
  • Addenbrooke's Charitable Trust, Cambridge University Hospitals (900275 Minute 47/20B)
  • Core Research for Evolutional Science and Technology (JPMJCR20H4)
  • Strategic International Collaborative Research Program
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
Delta variant, immune evasion, neutralizing antibodies, spike protein cleavage, syncytium formation, ChAdOx1 nCoV-19 vaccine, BNT162b2, vaccine effectiveness, receptor binding domain, N-terminal domain, airway organoids, healthcare workers, D614G
MeSH terms
SARS-CoV-2, COVID-19 Vaccines, Cell Fusion, Cell Line, Female, Health Personnel, Humans, India, Kinetics, Male, Vaccination, Virus Replication, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. https://app.cochat.ai/papers/10.1038/s41586-021-03944-y
The paper
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., Pandey, R., Brown, J., Zhou, J., Goonawardane, N., Mishra, S., Whittaker, C., Mellan, T., Marwal, R., Datta, M., . . . Gupta, R. K. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. https://doi.org/10.1038/s41586-021-03944-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.